This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Aveo's Kidney Cancer Drug Won't Get FDA Panel OK

Stocks in this article: AVEOONXXPFEGSK

Aveo believes overall survival of tivozanib was snake bit by a study design that allowed kidney cancer patients treated initially with Nexavar to receive effective, subsequent therapy, including tivozanib.

This chart explains Aveo's case:

Of the 257 kidney caner patients who started the study on Nexavar, 65% went on to receive additional therapy. The vast majority of these patients received tivozanib.

Of the 260 patients treated with tivozanib initially, only 26% went on to receive additional treatment, mostly other VEGF therapies like Pfizer's (PFE) Sutent or GlaxoSmithKline's (GSK) Votrient. Tivozanib is also a VEGF therapy.

Aveo argues that survival trended against tivozanib because the control patients (those who started on Nexavar) benefited from receiving more "add-on" therapy.

Point taken, and it could be enough to persuade the FDA panel to vote in the drug's favor next week. But what if we look at a more equitable comparison of tivozanib and Nexavar survival by examining only patients who received secondary therapy.

Here's that chart:

The top "A" graph depicts an overall survival analysis of "2 vs 2" line of therapy, meaning it compares overall survival of Tivozanib patients who went on to receive another therapy (two) versus Nexavar patients who also went on to receive another therapy (Two, with the vast majority receiving tivozanib.)

Uh oh, once again, overall survival trends in favor of the Nexavar control arm and against tivozanib. Two-year survival is 50% for the tivozanib arm compared to 64% for the Nexavar arm.

If tivozanib is a truly effective kidney cancer drug, why can't it demonstrate a survival benefit, even when patients are treated with another drug following tumor progression? If anything, the data from the study suggest tivozanib, if approved, should only be used after a patient is treated with Nexavar.

Take a look at the "B" graph now. This further drills down to analyze patients who only received subsequent treatment with another VEGF drug -- the most effective kidney cancer therapies. Yet again, the patients who began the study on Nexavar outlive the patients starting on tivozanib. (Two-year survival 63% vs. 55%.)

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,399.67 +19.26 0.12%
S&P 500 1,904.01 +17.25 0.91%
NASDAQ 4,316.0740 +57.6360 1.35%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs